Compare Halliburton Company (HAL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Repligen Corporation Common Stock — how do they compare? Halliburton Company trades at $32.54 (market cap $27.32B), while Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B). The key difference: Halliburton Company is far larger — about 2.5× Repligen Corporation Common Stock's market cap, and Halliburton Company pays a 2.07% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Repligen Corporation Common Stock for 0 Days on average.
| HAL | RGEN | |
|---|---|---|
Market Cap | $27.32B | $11.14B |
Volume | 5,347,556 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $42.98 | $194.57 |
52-Week Low | $21.82 | $102.87 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $33.47B | $11.02B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.83, up 0.71% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a P/E of 17.17 and ROE of 14.89%, though 2025 net income declined to $1.28B from $2.5B in 2024. Recent developments include Venezuela energy agreements and a Cyprus deepwater contract win, positioning for international growth amid volatile oil markets.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $43.11 price target, representing 31% upside. Key risks include oil price volatility and execution challenges in new markets. The stock offers value with reasonable valuation metrics but faces near-term headwinds from declining profitability trends.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
